O	0	1	[
B-intervention	1	10	Parecoxib
O	11	21	suppresses
O	22	25	the
O	26	34	increase
O	35	37	of
O	38	48	neutrophil
O	48	49	-
O	49	51	to
O	51	52	-
O	52	62	lymphocyte
O	63	68	ratio
O	69	74	after
O	75	78	the
O	79	87	modified
O	88	95	radical
O	96	106	mastectomy
O	106	107	]
O	107	108	.

O	109	111	To
O	112	119	observe
O	120	123	the
O	124	130	effect
O	131	133	of
O	134	143	parecoxib
O	144	146	on
O	147	157	neutrophil
O	157	158	-
O	158	160	to
O	160	161	-
O	161	171	lymphocyte
O	172	177	ratio
O	178	179	(
O	179	182	NLR
O	182	183	)
O	183	188	after
O	189	192	the
O	193	201	modified
O	202	209	radical
O	210	220	mastectomy
O	220	221	,
O	222	225	and
O	226	228	to
O	229	236	explore
O	237	240	its
O	241	250	potential
O	251	261	mechanisms
O	262	265	for
O	266	276	inhibition
O	277	279	of
O	280	293	perioperative
O	294	306	inflammation
O	306	307	.

O	308	315	Methods
O	315	316	:
O	317	318	A
O	319	324	total
O	325	327	of
B-total-participants	328	330	40
B-eligibility	331	337	breast
I-eligibility	338	344	cancer
I-eligibility	345	353	patients
I-eligibility	354	363	undergone
I-eligibility	364	367	the
I-eligibility	368	376	modified
I-eligibility	377	384	radical
I-eligibility	385	395	mastectomy
O	396	400	were
O	401	409	randomly
O	410	417	divided
O	418	422	into
O	423	424	a
O	425	434	parecoxib
O	435	440	group
O	441	442	(
O	442	443	n
O	443	444	=
B-intervention-participants	444	446	20
O	446	447	)
O	448	451	and
O	452	453	a
B-control	454	461	control
I-control	462	467	group
O	468	469	(
O	469	470	n
O	470	471	=
B-control-participants	471	473	20
O	473	474	)
O	474	475	.

O	476	479	The
O	480	489	parecoxib
O	490	495	group
O	496	504	received
O	505	516	intravenous
O	517	526	parecoxib
O	527	528	(
O	528	530	40
O	531	533	mg
O	533	534	,
O	535	536	5
O	537	539	mL
O	539	540	)
O	541	547	during
O	548	555	general
O	556	566	anesthesia
O	567	576	induction
O	576	577	,
O	578	582	post
O	582	583	-
O	583	592	operative
O	593	596	day
O	597	598	1
O	599	602	and
O	603	606	day
O	607	608	2
O	608	609	;
O	610	613	the
O	614	621	control
O	622	627	group
O	628	636	received
O	637	648	intravenous
O	649	655	normal
O	656	662	saline
O	663	664	(
O	664	665	5
O	666	668	mL
O	668	669	)
O	670	672	at
O	673	676	the
O	677	690	corresponding
O	691	695	time
O	696	702	points
O	702	703	.

O	704	709	Their
O	710	720	peripheral
O	721	727	bloods
O	728	732	were
O	733	742	collected
O	743	746	for
O	747	754	routine
O	755	759	test
O	760	762	in
O	763	766	the
O	767	774	morning
O	775	777	of
O	778	781	the
O	782	789	surgery
O	790	793	day
O	794	795	(
O	795	797	T1
O	797	798	)
O	798	799	,
O	800	803	and
O	804	807	Day
O	808	809	1
O	810	811	(
O	811	813	T2
O	813	814	)
O	814	815	,
O	816	819	Day
O	820	821	3
O	822	823	(
O	823	825	T3
O	825	826	)
O	827	830	and
O	831	834	Day
O	835	836	7
O	837	838	(
O	838	840	T4
O	840	841	)
O	842	847	after
O	848	851	the
O	852	859	surgery
O	859	860	,
O	861	864	and
O	865	868	NLR
O	869	872	was
O	873	883	calculated
O	883	884	.

O	885	892	Results
O	892	893	:
O	894	902	Compared
O	903	907	with
O	908	910	T1
O	910	911	,
B-outcome	912	915	NLR
O	916	918	in
O	919	922	the
O	923	930	control
O	931	936	group
O	937	939	at
O	940	942	T2
O	943	946	and
O	947	949	T3
O	950	953	was
O	954	967	significantly
O	968	977	increased
O	978	979	(
O	979	980	P
O	980	981	<
O	981	982	0
O	982	983	.
O	983	985	05
O	985	986	)
O	986	987	,
O	988	991	but
O	992	995	not
O	996	998	at
O	999	1001	T4
O	1002	1003	(
O	1003	1004	P
O	1004	1005	>
O	1005	1006	0
O	1006	1007	.
O	1007	1009	05
O	1009	1010	)
O	1010	1011	;
O	1012	1015	NLR
O	1016	1018	in
O	1019	1022	the
O	1023	1032	parecoxib
O	1033	1038	group
O	1039	1042	was
O	1043	1050	sharply
O	1051	1060	increased
O	1061	1063	at
O	1064	1066	T2
O	1067	1068	(
O	1068	1069	P
O	1069	1070	<
O	1070	1071	0
O	1071	1072	.
O	1072	1074	01
O	1074	1075	)
O	1075	1076	,
O	1077	1080	and
O	1081	1089	returned
O	1090	1092	to
O	1093	1105	preoperative
O	1106	1112	levels
O	1113	1115	at
O	1116	1118	T3
O	1119	1122	and
O	1123	1125	T4
O	1126	1127	(
O	1127	1128	P
O	1128	1129	>
O	1129	1130	0
O	1130	1131	.
O	1131	1133	05
O	1133	1134	)
O	1134	1135	.

B-outcome	1136	1139	NLR
O	1140	1142	in
O	1143	1146	the
O	1147	1156	parecoxib
O	1157	1162	group
O	1163	1166	was
O	1167	1180	significantly
O	1181	1186	lower
O	1187	1191	than
O	1192	1196	that
O	1197	1199	in
O	1200	1203	the
O	1204	1211	control
O	1212	1217	group
O	1218	1220	at
O	1221	1223	T2
O	1224	1225	(
O	1225	1226	P
O	1226	1227	<
O	1227	1228	0
O	1228	1229	.
O	1229	1231	05
O	1231	1232	)
O	1232	1233	,
O	1234	1237	but
O	1238	1243	there
O	1244	1248	were
O	1249	1251	no
O	1252	1263	significant
O	1264	1274	difference
O	1275	1282	between
O	1283	1286	the
O	1287	1290	two
O	1291	1297	groups
O	1298	1300	at
O	1301	1306	other
O	1307	1311	time
O	1312	1318	points
O	1319	1320	(
O	1320	1321	P
O	1321	1322	>
O	1322	1323	0
O	1323	1324	.
O	1324	1326	05
O	1326	1327	)
O	1327	1328	.

O	1329	1339	Conclusion
O	1339	1340	:
O	1341	1350	Parecoxib
O	1351	1354	can
O	1355	1363	restrain
O	1364	1367	the
O	1368	1380	inflammatory
O	1381	1390	responses
O	1391	1394	and
O	1395	1402	improve
O	1403	1409	immune
O	1410	1418	function
O	1419	1421	of
O	1422	1425	the
O	1426	1432	breast
O	1433	1439	cancer
O	1440	1448	patients
O	1449	1451	by
O	1452	1463	suppressing
O	1464	1467	the
O	1468	1477	elevation
O	1478	1480	of
O	1481	1484	NLR
O	1485	1490	after
O	1491	1494	the
O	1495	1503	modified
O	1504	1511	radical
O	1512	1522	mastectomy
O	1522	1523	,
O	1524	1529	which
O	1530	1532	is
O	1533	1541	expected
O	1542	1544	to
O	1545	1552	improve
O	1553	1556	the
O	1557	1566	prognosis
O	1567	1569	of
O	1570	1573	the
O	1574	1580	breast
O	1581	1587	cancer
O	1588	1596	patients
O	1596	1597	.
